Assessing the Impact of Calcium Channel Blockers on COGnitive Function in the Very Elderly (AI-COG)

Older adults are at increased risk of high blood pressure and cognitive decline. High blood pressure itself also increases risk of cognitive decline. A particular type of blood pressure lowering drug (a calcium channel blocker(CCB)) may lower risk of dementia in younger adults but there is no clear evidence of it's impact in those >=80. It is important that we know whether CCB use impacts on cognitive function in this age group. This study will examine the impact of antihypertensives on change in cognitive function with a particular focus on CCBs.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cognitive Ability, General Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cognition Disorders Cognitive Dysfunction Dementia High Blood Pressure Hypertension Mental Disorders Nervous System Diseases Neurocognitive Disorders Vascular Diseases

Age range

80 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

The Kiltearn Medical Centre, Nantwich, Cheshire, United Kingdom

About this study

This study is an observational cohort study examining cognitive change in those participants taking antihypertensives and aged 80 and over and examining cognitive change in participants taking different types of antihypertensive medication.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Aged 80 and over Receiving pharmacological treatment for hypertension Mini Mental State Exam score >24 No other condition likely to limit life to less than one year or to prevent the taking of informed consent.

Exclusion criteria

Aged under 80 years Not receiving pharmacological treatment for hypertension Mini Mental State Exam score <25 Diagnosed with a condition likely to limit life to less than one year or to prevent the taking of informed consent.

Presence of a sensory impairment or an existing neuropsychological deficit of sufficient severity to prevent cognitive testing.

Presence of a condition that will prevent cognitive testing, registered blind, profoundly deaf, suffering from an aphasia.

Treatment and study plan

Primary outcomes

Change in Cognitive Function as Measured Using the Extended Mini Mental State Exam

Time frame: 12 months

The change in cognitive function measured using the extended mini-mental state exam (this is an extended screening test which assesses several areas of cognitive function, the scale is from 0-100, higher scores are better, those without cognitive impairment would be expected to score close to maximum)

Sponsors and collaborators

Lead sponsor

Imperial College London

Other

Registry information

Important dates

Study start: 2013
Primary completion: 2015
Study completion: 2016
First posted: Jun 4, 2013
Registry last updated: Sep 23, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed